Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000220812 | SCV000269214 | benign | not specified | 2014-11-24 | criteria provided, single submitter | clinical testing | Ser769Ser in exon 20 of LARS2: This variant is not expected to have clinical sig nificance because it does not alter an amino acid residue and is not located wit hin the splice consensus sequence. It has been identified in 1.2% (51/4406) of A frican American chromosomes from a broad population by the NHLBI Exome Sequencin g Project (http://evs.gs.washington.edu/EVS; dbSNP rs143838895). |
Gene |
RCV000969009 | SCV000527597 | likely benign | not provided | 2021-06-29 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000220812 | SCV000859351 | benign | not specified | 2018-02-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000969009 | SCV001116500 | benign | not provided | 2025-01-13 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003917869 | SCV004733886 | benign | LARS2-related disorder | 2020-12-14 | no assertion criteria provided | clinical testing | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |